 |
BioWorld-International-2008-11-12
Ares Invests $13.5M in Santhera, Obtains 10.6% Stake in Firm
Xentech Seeks to Fund €4M Development Plan
No Abstract
BioWorld International Correspondent
PARIS - Xentech, a contract research start-up specialized in evaluating the efficacy of anticancer therapies, raised seed capital of €600,000 (US$765,000) from Aurinvest Capital 2, indicating that would help it put together a €4 million development plan.
Ares Invests $13.5M in Santhera, Obtains 10.6% Stake in Firm
Ares Life Sciences, a reported €1 billion (US$1.27 billion) investment vehicle established earlier this year by the Bertarelli family, former majority owners of Serono SA, has acquired a 10.6 percent stake in specialty pharmaceuticals firm Santhera Pharmaceuticals AG in return for CHF15.9 million (US$13.5 million). (BioWorld International)